Estamos realizando la búsqueda. Por favor, espere...
1583
37
170
29013
4402
2599
347
386
Abstract: Autoantibodies are a hallmark of autoimmunity and, specifically, antinuclear antibodies (ANAs) are the most relevant autoantibodies present in systemic autoimmune rheumatic diseases (SARDs). Over the years, different methods from LE cell to HEp-2 indirect immunofluorescence (IIF), solid-phase assays (SPAs), and finally multianalyte technologies have been developed to study ANA-associated SARDs. All of them provide complementary information that is important to provide the most clinically valuable information. The identification of new biomarkers together with multianalyte platforms will help close the so-called "seronegative ga" and to correctly classify and diagnose patients with SARDs. Finally, artificial intelligence and machine learning is an area still to be exploited but in a next future will help to extract patterns within patient data, and exploit these patterns to predict patient outcomes for improved clinical management.
Autoría: Irure-Ventura J., López-Hoyos M.,
Fuente: Diagnostics 2022, 12, 647
Año de publicación: 2022
Nº de páginas: 12
Tipo de publicación: Artículo de Revista
DOI: 10.3390/diagnostics12030647
ISSN: 2075-4418
Consultar en UCrea Leer publicación
JUAN IRURE VENTURA
MARCOS LOPEZ HOYOS
Volver